Over-the-counter acne treatments: A review

Journal of Clinical and Aesthetic Dermatology

Volumn 5, Issue 5, 2012, Pages 32-40

  Decker, Ashley ^a   Graber, Emmy M ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYACID; ANTI ACNE AGENT; BENZOYL PEROXIDE; BETA HYDROXYACID; CLINDAMYCIN; COSMETIC; DETERGENT; DOXYCYCLINE; ERYTHROMYCIN; GLUCONATE ZINC; GLUCONOLACTONE; HYDROXYACID; LACTOBIONIC ACID; MINOCYCLINE; NICOTINAMIDE; NON PRESCRIPTION DRUG; RETINOL; SALICYLIC ACID; SOAP; STRIDEX; SURFACTANT; TEA TREE OIL; TETRACYCLINE; TRICLOCARBAN; TRICLOSAN; TRIMETHOPRIM; UNCLASSIFIED DRUG; ZINC;

ACNE; ACNE VULGARIS; ADHESIVE PAD; BURNING SENSATION; COMEDO; DESQUAMATION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG TOLERABILITY; ERYTHEMA; HEATING DEVICE; HUMAN; KERATINIZATION; MEDICAL DEVICE; PH; PROPIONIBACTERIUM ACNES; REVIEW; SKIN CARE; SKIN IRRITATION; STAPHYLOCOCCUS AUREUS;

EID: 84863702063     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Goulden V, Stables I, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999;41:577-580. (Pubitemid 29480407)
2. Bowe W, Shalita AR. Effective over-the-counter acne treatments. Semin Cutan Med Surg. 2008;27(3):170-176.
3. Lehmann HP, Andrews JS, Robinson KA, et al. Management of Acne. Rockville (MD): Agency for Healthcare Research and Quality (US); 2001.
4. Casserly M. Proactiv's active ingredient. Forbes Magazine Online. http://www.forbes.com/sites/meghancasserly/2010/11/30/proactiv-celebrity- endorsement-katy-perry-lindsaylohan-justin-bieber/. Accessed June 21, 2011
5. Bergfeld WF. The evaluation and management of acne: economic considerations. J Am Acad Dermatol. 1995;32: S52-S56.
6. Kessler E, Flanagan K, Chia C, Rogers C, Glaser DA. Comparison of alpha and beta hydroxy acid chemical peels in treatment of mild to moderately severe facial acne vulgaris. Dermatol Surg. 2007;34(1):45-51.
7. Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther. 2004;17(Suppl 1):26-34.
8. Abbas S, Goldberg JW, Massaro M. Personal cleanser technology and clinical performance. Dermatol Ther. 2004;17(Suppl 1):35-42.
9. Korting HC, Ponce-Poschl E, Klovekorn G, Schmotzer G. The influence of the regular use of a soap or an acidic syndet bar on pre-acne. Infection. 1995;23:89-93.
10. Choi JM, Lew VK, Kimball AB. A single-blinded, randomized, controlled clinical trial evaluating the effect of face washing on acne vulgaris. Pediatr Dermatol. 2006;23(5):421-427. (Pubitemid 44434846)
11. Solomon BA, Shalita AR. Effects of detergent on acne. Clin Dermatol. 1996;14:95-99.
12. Baranda L, Gonzalez-Amaro R, Torres-Alvarez B, Alvarez C, Ramirez V. Correlation between pH and irritant effect of cleansers marketed for dry skin. Int J Dermatol. 2002;41:494-499. (Pubitemid 35021489)
13. Chalker DK, Shalita A, Smith GJ, Swann, RW. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol. 1983;9(6):933-936. (Pubitemid 14206988)
14. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology. 1998;196:119-125. (Pubitemid 28116058)
15. Leyden JJ. Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol. 2001;15(Suppl 3):51-55. (Pubitemid 34040987)
16. Eady EA, Bojar RA, Jones CE, et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin resistant propionibacteria. Br J Dermatol. 1996;134:107-113. (Pubitemid 26030998)
17. Thiboutot DM, Weiss, J, Bucko A, et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multiceneter, randomized, double-blind controlled study. J Am Acad Dermatol. 2007;57(5):791-799. (Pubitemid 47553072)
18. Mills OH, Kilgman AM, Pochi P, Comite H. Comparing 2.5%, 5% and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol. 1986;25(10):664-667. (Pubitemid 17210594)
19. Sawleshwarkar SN, Salgaonkar V, Oberai CM. Multicenter study to evaluate efficacy and irritation potential of benzoyl peroxide 4% cream in hydrophase base (Brevoxyl) in acne vulgaris. Indian J Dermatol Venereol Leprol. 2003;69:19-22. (Pubitemid 44943138)
20. Tung RC, Bergfeld WF, Vidimos AT, Remzi BK. Alpha hydroxy acid-based cosmetic procedures: guidelines for patient management. Am J Clin Dermatol. 2000;1(2):81-88.
21. Ditre CM, Griffin TD, Murphy GF, et al. Effects of alpha-hydroxy acids on photoaged skin: a pilot clinical, histologic, and ultrastructural study. J Am Acad Dermatol. 1996;34:187-195. (Pubitemid 26064761)
22. Van Scott EJ, Yu RJ. Hyperkeratinization, corneocyte adhesion, and alpha hydroxy acids. J Am Acad Dermatol. 1984;11:867-879. (Pubitemid 15201330)
23. Kaminsky A. Less common methods to treat acne. Dermatology. 2003;206:68-73. (Pubitemid 36167824)
24. Shalita AR. Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis. 1981;28:556-561. (Pubitemid 12171480)
25. Kessler E, Flanagan K, Chia C, Rogers C, Glaser DA. Comparison of α- and β- hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatol Surg. 2008;34(1):45-51.
26. Brubacher JR, Hoffman RS. Salicylism from topical salicylates: review of the literature. J Toxicol Clin Toxicol. 1996;34:431-436.
27. Briden ME, Green BA. The next generation of hydroxyacids. In: Draelos Z, Dover J, Alam M, eds. Procedures in Cosmetic Dermatology: Cosmecueticals. Philadelphia: Elsevier Saunders; 2005:205-212.
28. Grimes PE, Green BA, Wildnauer RH, et al. The use of polyhydroxy acids (PHAs) in photoaged skin. Cutis. 2004;73(Suppl 2):3-13. (Pubitemid 38315467)
29. Sasatsu M, Shimizu K, Noguchi N, Kono M. Triclosan-resistant Staphylococcus aureus. Lancet. 1993;341(8847):256.
30. Truter I. Evidence-based pharmacy practice: acne vulgaris. SA Pharma J. 2009;76:12-19.
31. Draelos ZD. Reexamining methods of facial cleansing. Cosmetic Dermatol. 2005;18(2):173-175. (Pubitemid 40270255)
32. Mills OH, Kligman AM. Evaluation of abrasives in acne therapy. Cutis. 1979;23(5):704-705. (Pubitemid 9167863)
33. Del Rosso JQ. A 6% benzoyl peroxide foaming cloth cleanser used in the treatment of acne vulgaris. J Clin Aesthet Dermatol. 2009;2(7):26-29.
34. Elston DM, White LC. Treatment of trichostasis spinulosa with a hydroactive adhesive pad. Cutis. 2000;66(1):77-78.
35. Clarisonic sonic cleansing effectively removes makeup. http://cdn.clarisonic.com/cdn/includes/pdfs/research-studies/cleansing-research/ effectively-removes-makeup.pdf Accessed April 10, 2011.
36. Bruce S, et al. Significant efficacy and safety of low level intermittent heat in patients with mild to moderate Acne. http://www.myzeno.com. Accessed Nov 16, 2011.
37. Raman A, et al. Antimicrobial effects of tea-tree oil and its major components on Staphylococcus aureus, Staphylococcus epidermidis and Propionibacterium acnes. J Appl Microbiol. 1995;21(4):242-245.
38. Hammer KA, Carson CF, Riley TV. Susceptibility of transient and commensal skin flora to the essential oil of Melaleuca alternifolia (tea tree oil). Am J Infect Control. 1996;24:186-189. (Pubitemid 26231018)
39. Buck DS, Nidorf DM, Addino JG. Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alterniforlia (Tea Tree) Oil and clotrimazole. J Fam Pract. 1994;38(6):601-605. (Pubitemid 24182908)
40. Cox SD, Mann CM, Markham JL, et al. The mode of antimicrobial action of the essential oil of Melaleuca alternifolia (tea tree oil). J Appl Microbiol. 2000;88:170-175. (Pubitemid 30140195)
41. Basset IB, Pannowitz DL, Barnetson RS. A comparative study of tea-tree oil versus benzoyl peroxide in the treatment of acne. Med J Aust. 1990;153(8):455-458. (Pubitemid 20332232)
42. Enshaleh S, Jooya A, Siadat AM, Iraji F. The efficacy of 5% topical tea tree oil gel to moderate acne vulgaris: a randomized, double-blind placebo-controlled study. Ind J Derm Venereol Leprol. 2007;73(1):22-25. (Pubitemid 46347991)
43. Hart PH, Brand C, Carson CF, et al. Terepin-4-ol, the main component of the essential oil of Melaleuca alternifolia (tea tree oil), suppresses inflammatory mediator production by activated human monocytes. Inflamm Res. 2000;49(11):619-626.
44. Brand C, Ferrante A, Prager RH, et al. The water-soluble components of the essential oil of Melaleuca alternifolia (tea tree oil) suppress the production of superoxide by human monocytes, but not neutrophils, activated in vitro. Inflamm Res. 2001;50(4):213-219. (Pubitemid 32382247)
45. Zeinab K, Pearce AL, Satkunanathan N, et al. Regulation of wheal and flare by tea tree oil: complementary humana and rodent studies. J Invest Dermatol. 2004;123:683-690. (Pubitemid 39281609)
46. Veien NK, Rosner K, Skovgaard GL. Is tea tree oil an important contact allergen? Contact Dermatitis. 2004;50(6):378-379. (Pubitemid 39070769)
47. Carson CF, Hammer KA, Riley TV. Melaleuca alternifolia (Tea Tree) oil: a review of antimicrobial other medicinal properties. Clin Micro Rev. 2006;19(1):50-62. (Pubitemid 43158450)
48. Aspres N, Freeman S. Predictive testing for irritancy and allergenicity of tea tree oil in normal human subjects. Exog Dermatol. 2003;2:258-261. (Pubitemid 38916088)
49. Kligman LH, Gans EH. Re-emergence of topical retinol in dermatology. J Dermatol Treat. 2000;11:47-52. (Pubitemid 30171151)
50. Draelos ZD, Thaman LD, eds. Cosmetic Formulation of Skin Care Products. New York: Taylor & Francis Group. 2006:276-278.
51. Kang S, Duell E, Fisher GJ, et al. Application of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels or irritation. J Invest Dermatol. 1995;105(4):549-556.
52. Duell EA, Kang S, Voorhees JJ. Unoccluded retinol penetrates human skin in vivo more effectively than unoccluded retinyl palmitate or retinoic acid. J Invest Dermatol. 1997;109:301-305. (Pubitemid 27394641)
53. Weiss JS. Current options for the topical treatment of acne vulgaris. Pediatric Dermatol. 1997;14(6):480-488. (Pubitemid 28012033)
54. Tan HH. Topical antibacterial treatments for acne vulgaris. Am J Clin Dermatol. 2004;5(2):79-84.
55. Katsambas A, Dessinioti C. New and emerging treatments in dermatology. Dermatol Ther. 2008;21:86-95.
56. Dreno B, Moyse D, Alirezai M, et al. Muticenter, randomized, comparative, double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Dermatology. 2001;203(2):135-140. (Pubitemid 34701573)
57. Grange PA, Raingeaud J, Calvez V, Dupin N. Nicotinamide inhibits Propionibacterium acnes-induced IL-8 production in keratinocytes through NF-kB and MAPK pathways. J Dermatol Science. 2009;56:106-12.
58. Griffiths CEM. Nicotinamde 4% gel for the treatment of inflammatory acne vulgaris. J Dermatol Treat. 1996;6(Suppl 1):8-10.
59. Savage LJ, Layton AM. Treating acne vulgaris: systemic, local and combination therapy. Expert Rev Clin Pharmacol. 2010;18:563.
60. Niren NM, Torok HM. The Nicotinamde improvement in clinical outcomes study (NICOS): results of an 8-week trial. Cutis. 2006;77(Suppl 1):17-28. (Pubitemid 43189145)
61. Lin AN, Relmer RJ, Carter DM. Sulfur revisited. J Am Acad Dermatol. 1988;18:553-558. (Pubitemid 18082470)